L and J-HZ by L&J Bio for Herpes Zoster (Shingles): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 19, 2024
L and J-HZ is under clinical development by L&J Bio and currently in Phase I for Herpes Zoster (Shingles).
clinical zoster 
40 
VTP-400 by Barinthus Biotherapeutics for Herpes Zoster (Shingles): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 20, 2023
VTP-400 is under clinical development by Barinthus Biotherapeutics and currently in Phase I for Herpes Zoster (Shingles).
Join 33,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Shingles vaccine offers a decade of protection in older adults
European Pharmaceutical Review
OCTOBER 21, 2022
GSK announced Shingrix (Zoster Vaccine Recombinant, Adjuvanted), the first approved shingles vaccine to combine a non-live antigen with a GSK-made adjuvant, can prevent shingles (herpes zoster) for at least decade. Shingles occurs when the varicella zoster virus (VZV) is reactivated in a patient.
Japan’s MHLW accepts GSK’s submission for shingles vaccine in adults
Pharmaceutical Technology
JUNE 29, 2022
The Japanese Ministry of Health, Labour and Welfare (MHLW) has accepted GlaxoSmithKline’s (GSK) regulatory application for recombinant, adjuvanted Zoster vaccine, Shingrix, for preventing shingles (herpes zoster) in at-risk adults of the age 18 years and above.
Look out GSK, Pfizer and BioNTech are coming for Shingrix
pharmaphorum
JANUARY 5, 2022
Having already brought their mRNA-based CVID-19 vaccine Comirnaty to market at breakneck speed, Pfizer and BioNTech are hoping to fast-track a vaccine for shingles based on the same technology platform through clinical development, with trials due to start later this year.
China’s CanSino seeks more vaccine contracts after AstraZenca deal
Express Pharma
AUGUST 31, 2023
The company has paused its clinical trials for mRNA COVID vaccine candidates, and will explore using the technology for other diseases. It is now developing an inhalable vaccine against the zoster virus, as the inhalable COVID vaccine stimulated strong mucosal immunisation and a robust immune response, Yu said. million yuan ($106.5
GSK wants to double Shingrix sales, and a new FDA okay could help
pharmaphorum
JULY 27, 2021
The FDA review was based mainly on a clinical trial showing that Shingrix was able to protect younger patients undergoing a bone marrow transplant for haematological cancers from developing shingles, but also included data from people immune-suppressed due to HIV, solid tumour and renal transplants.
Let's personalize your content